Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikulaa Parachuri

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Ocular Immunology and Inflammation|November 4, 2022
Immunogenicity: Clouding the Future of Intravitreal TherapyAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Journal of Vitreoretinal Diseases|November 17, 2023
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal DiseasesAshish Sharma, Anat Loewenstein, Nikulaa Parachuri, et al.
Indian Journal of Ophthalmology|June 1, 2022
Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in IndiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|October 17, 2022
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Ocular Immunology and Inflammation|July 9, 2021
Faricimab: Two in the Bush Is Proving Better than One in the Hand?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|March 29, 2024
Global experience of faricimab in clinical settings - a reviewAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 4, 2024
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|November 5, 2023
Aflibercept biosimilars - update on the development progressAshish Sharma, Anat Loewenstein, Nilesh Kumar, et al.
Eye (London, England)|June 23, 2021
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|January 20, 2022
On label bevacizumab for retina: where it standsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Ocular Immunology and Inflammation|November 4, 2022
Immunogenicity: Clouding the Future of Intravitreal TherapyAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Journal of Vitreoretinal Diseases|November 17, 2023
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal DiseasesAshish Sharma, Anat Loewenstein, Nikulaa Parachuri, et al.
Indian Journal of Ophthalmology|June 1, 2022
Supplemental nutrition for retinal health: Evidence based analysis of commercial preparations in IndiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|October 17, 2022
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Ocular Immunology and Inflammation|July 9, 2021
Faricimab: Two in the Bush Is Proving Better than One in the Hand?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|March 29, 2024
Global experience of faricimab in clinical settings - a reviewAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|March 4, 2024
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|November 5, 2023
Aflibercept biosimilars - update on the development progressAshish Sharma, Anat Loewenstein, Nilesh Kumar, et al.
Eye (London, England)|June 23, 2021
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|January 20, 2022
On label bevacizumab for retina: where it standsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Pageof 7